The Changing Outlook for Immunotherapies in Cancer Treatment
Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.
Howard L. Kaufman, MD, Rush University Medical Center, comments on the changing outlook for immunotherapies.
Recently, Kaufman says, immunotherapies have been meeting their endpoints in clinical trials and are being associated with durable responses. Further, immunotherapies seem to demonstrate overall survival benefit, which is completely changing the outlook for the class of agents. Immunotherapies are gaining more widespread support and acceptance.
Clinical Pearls
There remains a need for more research to understand the mechanisms of immunotherapies and to identify predictive biomarkers to get appropriate patients into studies sooner. Researchers are also looking at a vast array of potential combinations of immunotherapies.
- Immunotherapies have been meeting endpoints in clinical trials and seem to be demonstrating overall survival benefit
- There is a need for more research into immunotherapies to understand how they work and to identify predictive biomarkers
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More
